IP Library Granted Patent US 9,428,797
Granted Patent B2
US 9,428,797 · App. 10/902,682 · Granted Aug 30, 2016

Nucleic acid detecting or quantifying processes

Inventors: Elazar Rabbani (New York, NY); Jannis G. Stavrianopoulos (Bayshore, NY); James J. Donegan (Long Beach, NY); Jack Coleman (East Northport, NY)
Assignee: Enzo Life Sciences, Inc.
C12Q1/6837C07H21/00C12N15/1058C12Q1/6809C12Q1/6825C07B2200/11C40B40/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,428,797
App. No.
10/902,682
Granted
Aug 30, 2016
Kind
B2
Abstract

This invention provides novel compositions and processes for analyte detection, quantification and amplification. Nucleic acid arrays and libraries of analytes are usefully incorporated into such compositions and processes. Universal detection elements, signaling entities and the like are employed to detect and if necessary or desirable, to quantify analytes. Amplification of target analytes are also provided by the compositions and processes of this invention.

Claims (37)

1. A process for detecting or quantifying non-nucleic analytes of interest, said process comprising the steps of:

1) providing:

a) a sample comprising analytes, said analytes of the sample comprising or suspected of comprising one or more of a first non-nucleic acid analyte of interest and a second non-nucleic acid analyte of interest, wherein

said non-nucleic acid analytes comprise oligopeptides, polypeptides, oligosaccharides, polysaccharides, lipids, ligands, or combinations thereof;

b) an array on a solid surface, said array comprising a plurality of discrete areas; wherein

at least two of said discrete areas comprise a first discrete area and a second discrete area, said first discrete area and said second discrete area comprising a chimeric composition consisting of a nucleic acid portion covalently bound to a non-nucleic acid portion;

said nucleic acid portion of the chimeric composition located at said first discrete area has a different sequence from that of said nucleic acid portion of the chimeric composition located at said second discrete area;

said covalently bound non-nucleic acid portion of the chimeric composition of said first discrete area has a binding affinity for the first non-nucleic acid analyte of interest,

said covalently bound non-nucleic acid portion of the chimeric composition of said second discrete area has a binding affinity for the second non-nucleic acid analyte,

said first non-nucleic acid analyte is different from said second non-nucleic acid analyte, and

when the non-nucleic acid portion is a peptide or protein, the nucleic acid portion does not comprise a sequence which is either identical or complementary to a sequence that codes for said peptide or protein; and

c) signal generating means;

2) labeling said non-nucleic acid analytes of the sample with said signal generating means;

3) contacting said array with said labeled non-nucleic acid analytes under conditions permissive of binding said labeled non-nucleic acid analytes to said non-nucleic acid portion; and

4) detecting or quantifying the presence of said first and second non-nucleic acid analytes of interest by measuring said signal generating means respectively bound to said first and second discrete areas of said array.

2. The process of claim 1 , wherein said solid surface is porous.

3. The process of claim 2 , wherein said porous solid surface comprises polyacrylamide or agarose.

4. The process of claim 1 , wherein said solid surface is non-porous.

5. The process of claim 4 , wherein said non-porous solid surface comprises glass or plastic.

6. The process of claim 2 , wherein said solid surface is transparent, translucent, opaque or reflective.

7. The process of claim 1 , wherein said nucleic acid portion comprises DNA, RNA, a DNA analog, an RNA analog, or combinations thereof.

8. The process of claim 7 , wherein said nucleic acid portion comprises PNA.

9. The process of claim 7 or 8 , wherein said nucleic portion is modified on any of the sugar, phosphate or base moieties.

10. The process of claim 1 , wherein said nucleic acid portions are directly or indirectly fixed or immobilized to said solid surface.

11. The process of claim 1 , wherein said non-nucleic acid portions comprise peptides, proteins, ligands, enzyme substrates, hormones, receptors, drugs, or a combination of any of the foregoing.

12. The process of claim 1 , wherein said signal generating means comprises a direct signal generating means.

13. The process of claim 12 , wherein said direct signal generating means comprises a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, a chelating compound, an electron dense compound, a magnetic compound, an intercalating compound, an energy transfer compound, or a combination of any of the foregoing.

14. The process of claim 1 , wherein said signal generating means comprise an indirect signal generating means.

15. The process of claim 14 , wherein said indirect signal generating means comprises an antibody, an antigen, a hapten, a receptor, a hormone, a ligand, an enzyme, or a combination of any of the foregoing.

16. The process of claim 15 , wherein said indirect signal generating means comprises an enzyme that catalyzes a reaction comprising a fluorogenic reaction, a chromogenic reaction or a chemiluminescent reaction.

17. The process of claim 1 , wherein said non-nucleic acid analytes comprise ligands comprising non-peptide antigens, hormones, enzymes, substrates, vitamins, drugs, non-peptide signal molecules, or combinations thereof.

18. The process of claim 1 , wherein said non-nucleic acid analytes of the sample comprise polypeptides and one or both of the first and second non-nucleic acid analytes of interest are polypeptides.

19. The process of claim 18 , wherein said solid surface is non-porous.

20. The process of claim 1 , wherein said non-nucleic acid analytes of the sample comprise oligopeptides and one or both of the first and second non-nucleic acid analytes of interest are oligopeptides.

21. The process of claim 1 , wherein said non-nucleic acid analytes of the sample comprise polysaccharides and one or both of the first and second non-nucleic acid analytes of interest are polysaccharides.

22. The process of claim 1 , wherein said non-nucleic acid analytes of the sample comprise lipids and one or both of the first and second non-nucleic acid analytes of interest are lipids.

23. The process of claim 1 , wherein said non-nucleic acid analytes of the sample comprise ligands and one or both of the first and second non-nucleic acid analytes of interest are ligands.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2015
From: RABBANI, ELAZAR; STAVRIANOPOULOS, JANNIS G.; DONEGAN, JAMES J.; COLEMAN, JACK
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 036770/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2015
From: RABBANI, ELAZAR; STAVRIANOPOULOS, JANNIS G.; DONEGAN, JAMES J.; COLEMAN, JACK
To: ENZO LIFE SCIENCES, INC.
Reel/Frame 036771/0115 →
Continuity (2)
Division 09896897 · Jun 30, 2001
Related Publication 20060014156A1 · Jan 19, 2006